Your browser doesn't support javascript.
loading
Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma.
Pinato, David J; Kaneko, Takahiro; D'Alessio, Antonio; Forner, Alejandro; Fessas, Petros; Minguez, Beatriz; Giannini, Edoardo G; Grillo, Federica; Díaz, Alba; Mauri, Francesco A; Fulgenzi, Claudia A M; Dalla Pria, Alessia; Goldin, Robert D; Pieri, Giulia; Toniutto, Pierluigi; Avellini, Claudio; Plaz Torres, Maria Corina; Akarca, Ayse U; Marafioti, Teresa; Bhoori, Sherrie; Miró, Jose María; Bower, Mark; Bräu, Norbert; Mazzaferro, Vincenzo.
Afiliación
  • Pinato DJ; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, UK.
  • Kaneko T; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
  • D'Alessio A; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, UK.
  • Forner A; Tokyo Medical and Dental University, Tokyo, Japan.
  • Fessas P; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, UK.
  • Minguez B; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
  • Giannini EG; Liver Unit, Barcelona Clinic Liver Cancer (BCLC) Group, ICMDM, Hospital Clinic Barcelona, IDIBAPS. University of Barcelona, Barcelona, Spain.
  • Grillo F; National Biomedical Research Institute on Liver and Gastrointestinal Diseases (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain.
  • Díaz A; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, UK.
  • Mauri FA; Liver Unit, Department of Internal Medicine Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain.
  • Fulgenzi CAM; Vall d'Hebron Institute of Research (VHIR), CIBERehd Vall d'Hebron, Barcelona Hospital Campus, Barcelona, Spain.
  • Dalla Pria A; Gastroenterology Unit, Department of Internal Medicine, University of Genoa, IRCCS-Ospedale Policlinico San Martino, Genoa, Italy.
  • Goldin RD; Pathology Unit, Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, IRCCS-Ospedale Policlinico San Martino, Genoa, Italy.
  • Pieri G; National Biomedical Research Institute on Liver and Gastrointestinal Diseases (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain.
  • Toniutto P; Pathology Department, Hospital Clínic, University of Barcelona, Barcelona, Catalonia, Spain.
  • Avellini C; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, UK.
  • Plaz Torres MC; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, UK.
  • Akarca AU; Medical Oncology Department, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
  • Marafioti T; National Centre for HIV Malignancy, Department of Oncology, Chelsea & Westminster Hospital, London, UK.
  • Bhoori S; Centre for Pathology, Imperial College London, London, UK.
  • Miró JM; Gastroenterology Unit, Department of Internal Medicine, University of Genoa, IRCCS-Ospedale Policlinico San Martino, Genoa, Italy.
  • Bower M; Hepatology and Liver Transplantation Unit, Department of Medical Area (DAME), University of Udine, Udine, Italy.
  • Bräu N; Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia", Institute of Histopathology, Udine, Italy.
  • Mazzaferro V; Gastroenterology Unit, Department of Internal Medicine, University of Genoa, IRCCS-Ospedale Policlinico San Martino, Genoa, Italy.
JHEP Rep ; 5(7): 100741, 2023 Jul.
Article en En | MEDLINE | ID: mdl-37274775
Background & Aims: HIV-seropositivity shortens survival in patients with hepatocellular carcinoma (HCC). Although risk factors for HCC including HCV infection can influence T cell phenotype, it is unknown whether HIV can influence functional characteristics of the T cell infiltrate. Methods: From the Liver Cancer in HIV biorepository, we derived 129 samples of transplanted (76%) or resected (20%) HCC in eight European and North American centres. We profiled intra- and peritumoural tissue to evaluate regulatory CD4+/FOXP3+ and immune-exhausted CD8+/PD1+ T cells in HIV+ (n = 66) and HIV- (n = 63) samples. We performed targeted transcriptomics and T-cell receptor sequencing in a restricted subset of samples evaluated in relationship with HIV status. We correlated immunopathologic features with patients' characteristics including markers of HIV infection. Results: Of the 66 HIV+ patients, 83% were HCV coinfected with an undetectable HIV viral load (51%) and a median blood CD4+ cell count of 430 cells/mm3 (range 15-908). Patients who were HIV+ were compared with HIV- controls with similar staging characteristics including Barcelona Clinic Liver Cancer (BCLC) stage A-B (86% vs. 83%, p = 0.16), <3 nodules (90% vs. 83%, p = 0.3) and median alpha-foetoprotein values (10.9 vs. 12.8 ng/ml, p = 0.72). HIV+ samples had higher PD-L1 expression rates in tumour tissue (51% vs. 8% p <0.0001) and displayed denser intratumoural CD4+/FOXP3+ (p <0.0001), CD8+/PD1+ (p <0.0001), with lower total peritumoural CD4+ (p <0.0001) and higher peritumoural CD8+/PD1+ (p <0.0001). Gene set analysis revealed HIV+ cases to have evidence of dysregulated adaptive and innate immunity. Tumour-infiltrating lymphocyte clonality was not influenced by HIV status. Conclusions: HIV-associated HCC harbours a profoundly immune-exhausted tumour microenvironment, warranting prospective testing of immunotherapy in this treatment-deprived patient population. Impact and Implications: Hepatocellular carcinoma is a non-AIDS defining malignancy characterised by poor survival. The programmed cell death (PD-1) pathway governs antiviral and anticancer immune exhaustion and is a therapeutic target in HCC. This study highlights how HIV infection is associated with significantly higher PD-L1 expression in HCC cells and in the surrounding microenvironment, leading to changes in cytotoxic and regulatory T cell function and dysregulation of proinflammatory pathways. Taken together, our results suggest dysfunctional T cell immunity as a mechanism of worse outcome in these patients and suggest clinical testing of checkpoint inhibitors in HIV-associated HCC.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: JHEP Rep Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: JHEP Rep Año: 2023 Tipo del documento: Article